Should we undertake surveillance for HCC in patients with NAFLD ??

Slides:



Advertisements
Similar presentations
Hcv infection and management in advanced liver disease
Advertisements

Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer in the world and the third most common cause of cancer mortality.
Diabetes Mellitus.
V.E.I.L. Liver Cancer Prevention. 1. Vaccination Birth dose + 2 Universal for those not already chronics Screening pregnant women Catch up vaccination.
 Primary liver cancer is the fifth most common cancer in the world and the third most common cause of cancer mortality  Hepatocellular carcinomas (HCCs)
S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.
Sef lucrari Dr. Carmen Anton
Liver Cirrhosis S. Diana Garcia
What is Diabetes? Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
F ATTY L IVER Shahin Merat, M.D. Associate Professor of Medicine Digestive Disease Research Center, Tehran University of Medical Sciences, 8 th International.
Module 3: HCV prevalence and course of HCV infection.
NONALCOHOLIC STEATOHEPATITIS (NASH), NAFLD, ASH J. Horák Department od Medicine I Department od Medicine I Third Faculty of Medicine Third Faculty of Medicine.
Cholestatic liver diseases:
Hepatocellular Carcinoma (HCC). Definition : Hepatocellular carcinoma is a primary malignancy of the hepatocyte, also known as liver cell carcinoma. Types.
Surveillance for HCC. Surveillance in cancer Definition: Repeated application of a test over time with the aim of reducing disease-specific mortality.
Public Health Issues in Canada. What do you think are the current issues? 1.Consider if the issue is affecting more than a few individuals 2.Is it something.
Non-alcoholic Fatty Liver Disease
EPIDEMIOLOGICAL AND CLINICAL FEATURES OF LIVER CIRRHOSIS
FT in prognostic of HBV FibroTest: predictive value in HBV.
Plasminogen-Activating Inhibitor-1 (PAI-1) High PAI-1 associated with: Obesity (especially visceral), possible fatty liver. 2,3,4 Inflammation and oxidative.
Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.
Hepatocellular carcinoma related to Hbv and Hcv
“Hepatocellular Carcinoma” (HCC) By Faiza Asghar.
BRÍD MCHUGH C DT204/2 R&D ASSIGNMENT Primary Biliary Cirrhosis.
Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
GASTROENTEROLOGY 2010;138:493–502 심 재 준 월요 저널.
심 재 준심 재 준 Am J Gastroenterol 2007;102:
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
F. 정 회 훈 Am J Gastroenterol 2012;107:46-52 Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy:
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
ALCOHOLIC LIVER DISEASE. Alcohol is one of the most common causes of chronic liver disease worldwide,In the UK, a unit of alcohol contains 8 g of ethanol.
Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients Giovanni Targher, Lorenzo Bertolini, Felice Poli,
Treatment of HBV/HCV Coinfection
Introductions Introductions Definitions of terms Definitions of terms The basics The basics What causes cancers? What causes cancers? How do Cancers develop?
Fatty Liver and Liver Cancer In the Hispanic Community.
Pasi Erkkilä and Akseli Koskela
Alcoholic liver disease and non-alcoholic fatty liver disease
Hepatitis C.
Dr. Mohammed Omar Khalifa
Addressing Viral Hepatitis
DIFFERENCE IS SIGNIFICANT
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Metabolic Changes in Diabetes Mellitus
Hepatology Hepatitis C virus (HCV) genotype 1b as a risk factor
BY: Asmaa Alastal. wafaa hanouna. Salma abu taha. .Sara shaban
On the Rise: Liver Cancer in Iowa Donald J. Hillebrand, MD.
A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova
Underwriting Screening Liver Test Abnormalities:
Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2
Chronic viral hepatitis type B with “ground glass” cells
Non-alcoholic steatohepatitis with positive ANA
More Than Meets the Eye: Identifying Who Is at Risk for NASH
PNPLA3 gene in liver diseases
The New England Journal of Medicine (378;12) March 22, 2018
Genetics and epigenetics of NAFLD and NASH
Hepatology Hepatitis C virus (HCV) genotype 1b as a risk factor
T. Vescovo, G. Refolo, G. Vitagliano, G.M. Fimia, M. Piacentini 
HEPATOCELLULAR CARCINOMA (HCC) at
Nat. Rev. Nephrol. doi: /nrneph
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
Clinical outcome after SVR: ANRS CO22 HEPATHER
Example of algorithm for clinical assessment of patients at risk of non-alcoholic fatty liver disease Example of algorithm for clinical assessment.
Impact of metabolic risk factors on HCC
Hepatocellular Carcinoma in Patients with
Provider comparison reveals no difference between training levels
Public Health Policies and Alcohol-related Liver Disease
Fig. 4: Schematic, initial diagnostic algorithm for a patient presenting with mild aminotransferase abnormality. Fig. 4: Schematic, initial diagnostic.
Presentation transcript:

Should we undertake surveillance for HCC in patients with NAFLD ?? DR. Ahmed Zeid (MD) Ass.Prof. Internal Medicine HPB UNIT-Alexandria

The term NASH was first introduced by Ludwig and co-workers in 1980, when they described the histological findings that occurred in obese, diabetic patients (mainly women) who denied alcohol intake.

Up to 30% of adults in North America and Western Europe are known to have excess fat accumulation in the liver. Of these, nearly 10% have NASH, which represents 2%-3% of all adults. NAFLD may soon become one of the main causes of ESLD requiring liver transplantation in North America. Roberto HA et al. World J Gastroenterol. 2012

NAFLD HCC ?????

Major risk factors for HCC: Chronic hepatitis B, C, and D Toxins (e.g., alcohol, tobacco, aflatoxins) Hereditary metabolic liver diseases (e.g., hereditary hemochromatosis, α1 antitrypsin deficiency) Autoimmune hepatitis Cirrhosis Insulin resistance Overweight in males Diabetes mellitus NAFLD. Blum HE, et al. Arch Iranian Med 2007; 10: 361-71.

NAFLD is the most rapidly increasing cause of HCC, in parallel with the spread of obesity and diabetes in the general population.

The annual incidence of HCC in patients with HCV is 4% and NAFLD-cirrhosis 2.5%, while the 5- year incidence rises to 30% in HCV in comparison to 11% in NAFLD patients.

HCC can also develop in non- cirrhotic NAFLD, with hundreds of cases reported. The initial observation was made in a single-centre study in USA on 128 patients undergoing liver resection for HCC; 16 HCC occurence in livers without significant fibrosis was more frequent in patients with metabolic syndrome and NAFLD than in patients with liver disease of other etiologies

The life expectancy of NAFLD patients with HCC is generally thought to be poor because of their associated co-morbidity of MS that often limits therapeutic choices including orthotopic liver transplantation. Heuer M, et al.Digestion 2012;86:107-13

Patients with NAFLD cirrhosis had a significantly greater prevalence of advanced HCC stage, lower amenability to any treatment, and shorter survival times compared with HCV patients, because HCC in these patients is often diagnosed at an advanced stage owing to lack of surveillance Giannini et al Clin Gastroenterol Hepatol 2009;7:580-5

NAFLD-HCC multiple hits Risk factors for the development of HCC in NAFLD: Old age. Cirrhosis. Obesity especially visceral fat. Type 2 DM. Cardiovascular comorbidities. Genetic background: PNPLA3 rs738409 [G] risk allele, is repeatedly reported to increase risk of HCC by 12 fold. TERT, MBOAT other genes have been reported

HEPATOCARCINOGENESIS Ongoing chronic liver cell injury, inflammation, regeneration, fibrosis and subsequently cirrhosis can lead to uncontrolled focal liver cell growth and eventually HCC. Mostly, HCC slowly unfolds on a background of chronic inflammation triggered by exposure to HBV, HCV, toxic compounds (ethanol), or metabolic impairment.

NAFLD CARCINOGENESIS ?? insulin resistance + oxidative stress NASH-associated insulin resistance causes inhibition of hepatic mitochondrial fatty acid oxidation and increased intracellular fatty acids may lead to oxidative DNA damage. Insulin resistance with hyperinsulinaemia, Insulin-like growth factor 1 significantly activated MAPK and increased overexpression of proto-oncogenes in cultured hepatoma cells.

HCC Survillence NAFLD with cirrhosis: Poor surveillance is a constant problem. In a multicentre prospective study in Italy, which included 756 patients with HCC related either to NAFLD or HCV, 52% of patients with NAFLD-related HCC were not diagnosed on regular surveillance compared to 37% of patients with HCV-related HCC , resulting in more advanced HCC burden at diagnosis.

HCC Survillence NAFLD with cirrhosis: In a national USA cohort study from Veterans Administration hospitals, including 1,500 patients who developed HCC from 2005-2010, diagnosis was made by surveillance in 40% of patients with NAFLD compared to 80% of patients with HCV Surveillance for HCC occurrence in NAFLD-cirrhosis is included in ‘‘other conditions” in the AASLD guidelines for management of HCC with no specific recommendations.

HCC Survillence NAFLD with cirrhosis: Surveillance by abdominal ultrasound has a suboptimal performance in these patients, because of attenuation of ultrasound beam in bright liver, echostructural heterogeneity and focal fatty infiltration, leading to a high rate of underrecognition or misinterpretation of small nodules.

HCC Survillence Recently a scoring system based on age, sex, smoking, physical activity, medical history of DM, aminotransferases and AFP identified almost all HCC cases detected by U/S in high-risk Taiwanese patients. The PNPLA3 rs738409 C>G gene polymorphism might provide patient-risk stratification, but it is not considered cost-effective yet.

HCC Survillence NAFLD without cirrhosis: surveillance for HCC is deemed cost-effective if the expected risk of incident HCC exceeds a threshold of 1.5% per year, but epidemiological studies remain inadequate. In this specific subgroup, diagnosis of HCC should be established by liver biopsy

CONCLUSIONS The growing burden of NAFLD related HCC is becoming a serious challenge for public health, in terms of surveillance and treatment.

CONCLUSIONS We need more epidemiological and clinical data and a better understanding of the molecular events leading from obesity to NAFLD and HCC, particularly in patients without cirrhosis. This will enable the development of scoring algorithms and serological tests to stratify the risk of HCC in NAFLD patients.

THANK YOU

Prevention of HCC in NAFLD: what is possible? The earlier the exposure to risk factors, the earlier the onset of malignancy, particularly on a genetically predisposed background. The casual association with other ‘‘superimposed hits”, such as viral infection, alcohol abuse or adenoma formation.